Gene: ZBTB18
Official Full Name: zinc finger and BTB domain containing 18provided by HGNC
Gene Summary: This gene encodes a C2H2-type zinc finger protein which acts a transcriptional repressor of genes involved in neuronal development. The encoded protein recognizes a specific sequence motif and recruits components of chromatin to target genes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2013]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO31839 | ZBTB18 Knockout cell line (HeLa) | Human | ZBTB18 | 1:3~1:6 | Negative | Online Inquiry |
KO31840 | ZBTB18 Knockout cell line (HCT 116) | Human | ZBTB18 | 1:2~1:4 | Negative | Online Inquiry |
KO31841 | ZBTB18 Knockout cell line (HEK293) | Human | ZBTB18 | 1:3~1:6 | Negative | Online Inquiry |
KO31842 | ZBTB18 Knockout cell line (A549) | Human | ZBTB18 | 1:3~1:4 | Negative | Online Inquiry |
ZBTB18 Gene Knockout Cell Lines are specifically engineered cellular models that have undergone targeted gene disruption to explore the physiological and pathological roles of the zinc finger and BTB domain-containing protein 18 (ZBTB18). These knockout models enable researchers to study gene function and regulation, providing insights into cellular mechanisms governed by ZBTB18, which is known to play significant roles in transcriptional regulation, immune responses, and various neurodevelopmental processes.
The primary function of ZBTB18 Gene Knockout Cell Lines is to facilitate investigations into the signaling pathways and biological processes affected by the loss of this specific gene. By utilizing CRISPR-Cas9 or other advanced genomic editing technologies, these cell lines exhibit precise genetic modifications that allow researchers to observe phenotypic changes in the absence of ZBTB18, including alterations in differentiation patterns and cellular behavior. This makes them invaluable for functional assays, drug discovery, and the elucidation of disease mechanisms.
Scientifically, ZBTB18 knockout models are crucial for advancing our understanding of diseases such as neurodegenerative disorders, where dysregulation of transcription factors can significantly impact neuronal health. In clinical settings, these models can aid in the development of targeted therapies by revealing potential biomarkers and therapeutic targets for intervention.
Compared to alternative models, the specificity of ZBTB18 Gene Knockout Cell Lines provides a higher level of accuracy and reproducibility in experiments, minimizing off-target effects often associated with other methods. These cell lines are produced under rigorous quality control measures, ensuring that researchers gain reliable and consistent results for their studies.
For researchers, clinicians, and pharmaceutical companies, ZBTB18 Gene Knockout Cell Lines represent an essential tool for furthering biological research and therapeutic advancements. The elucidation of ZBTB18 functions could emerge as a powerful avenue for novel drug targets, bridging gaps in our understanding of gene regulation and disease pathology.
At our company, we are dedicated to providing high-quality, innovative biological products supported by extensive scientific expertise. Our commitment to advancing research and enabling breakthroughs in cellular and molecular biology is evident in our meticulous development of such specialized tools, ensuring that every researcher has access to the best resources for their scientific inquiries.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.